Core Points - Huazheng New Materials (603186) closed at 31.05 yuan on July 4, 2025, up 5.22% from last week's 29.51 yuan [1] - The company's market capitalization is currently 4.409 billion yuan, ranking 45th out of 56 in the components sector and 3359th out of 5149 in the A-share market [1] Company Announcements - As of June 30, 2025, a total of 67,000 yuan of "Huazheng Convertible Bonds" have been converted into company stock, resulting in 1,715 shares, which is 0.0012% of the total shares before conversion [1] - The remaining unconverted "Huazheng Convertible Bonds" amount to 569.933 million yuan, accounting for 99.9882% of the total issuance [1] - No "Huazheng Convertible Bonds" were converted into company stock between April 1, 2025, and June 30, 2025 [1] - The total share capital of the company remains unchanged at 142,012,027 shares [1] - The "Huazheng Convertible Bonds" were issued on January 24, 2022, with a face value of 100 yuan each, totaling 5.7 million bonds, with a maturity of six years and an increasing coupon rate from 0.20% in the first year to 2.00% in the sixth year [1] - The conversion period for the bonds is from July 28, 2022, to January 23, 2028, with the latest conversion price set at 38.51 yuan per share [1]

Summary of Key Points Core Viewpoint - The announcement details the conversion results of the convertible bonds issued by Zhejiang Huazheng New Materials Co., Ltd., highlighting the low conversion rate and the remaining unconverted bonds. Group 1: Convertible Bond Issuance Overview - The company issued a total of 5,700,000 convertible bonds in 2022, with a term of 6 years from January 24, 2022, to January 23, 2028, and a face interest rate that increases over the years, starting at 0.20% in the first year and reaching 1.50% by the fourth year [2][3]. Group 2: Conversion Status - As of June 30, 2025, a total of RMB 67,000 worth of convertible bonds have been converted into 1,715 shares, representing 0.0012% of the company's total shares before conversion [1][4]. - The total amount of unconverted convertible bonds as of June 30, 2025, is RMB 569,933,000, which accounts for 99.9882% of the total issuance [1][4]. Group 3: Recent Conversion Activity - From April 1, 2025, to June 30, 2025, there were no conversions of the convertible bonds into company stock, with a conversion amount of RMB 0 and a conversion quantity of 0 shares [3][4]. Group 4: Share Capital Changes - The total share capital remained unchanged at 142,012,027 shares, with no new shares issued from the convertible bond conversions [4][5].

南银转债：强赎 华海药业：公司收到FDA警告信 ("公司"）于近日收到美国食品药品监督管 理局（以下简称"FDA"）发出的警告信，该警告信系基于2025 年1 月16日至 1 月 24 日期 间 FDA 对公司位于临海市汛桥镇的药品生产基地进行的现场检查。警告信针对汛桥生产基地 的制剂产品提出了相关检查意见和改进建议，主要涉及部分口服固体生产设备清洁管理、无 菌生产区域维护和压片剔废参数研究的充分性。 公司高度重视 FDA 的建议，已积极采取措 施进行优化，并持续与FDA保持积极沟通。公司将持续提升质量管理体系，确保合规运营。 佳禾智能：股东拟减持不超1%公司股份 瑞丰高材：董事会秘书赵子阳因涉嫌内幕交易被立案 调查 华正转债，晶科转债：不下修 交大铁发：北交所新股【上市】 华之杰：沪深新股【申 购】 中金亦庄产业园REIT(508080)：【认购】 集思录(www.jisilu.cn)是一个以数据为本的投资理财社区，专注于新股、可转债、债券、封闭 基金等数据服务。我们的理念是在保证本金安全的前提下，使资产获得稳健增长。 关注集思录微信 特别提示 本文不构成任何投资建议，仅为信息分享。任何因本文导致的投资行为 ...